1. Home
  2. WCC vs VRNA Comparison

WCC vs VRNA Comparison

Compare WCC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WCC
  • VRNA
  • Stock Information
  • Founded
  • WCC 1922
  • VRNA 2005
  • Country
  • WCC United States
  • VRNA United Kingdom
  • Employees
  • WCC N/A
  • VRNA N/A
  • Industry
  • WCC Telecommunications Equipment
  • VRNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • WCC Consumer Discretionary
  • VRNA Health Care
  • Exchange
  • WCC Nasdaq
  • VRNA Nasdaq
  • Market Cap
  • WCC 10.3B
  • VRNA 8.3B
  • IPO Year
  • WCC 1999
  • VRNA 2017
  • Fundamental
  • Price
  • WCC $214.71
  • VRNA $106.43
  • Analyst Decision
  • WCC Buy
  • VRNA Buy
  • Analyst Count
  • WCC 9
  • VRNA 11
  • Target Price
  • WCC $232.67
  • VRNA $114.10
  • AVG Volume (30 Days)
  • WCC 574.9K
  • VRNA 1.3M
  • Earning Date
  • WCC 10-30-2025
  • VRNA 11-03-2025
  • Dividend Yield
  • WCC 0.84%
  • VRNA N/A
  • EPS Growth
  • WCC N/A
  • VRNA N/A
  • EPS
  • WCC 12.76
  • VRNA N/A
  • Revenue
  • WCC $22,232,400,000.00
  • VRNA $221,673,000.00
  • Revenue This Year
  • WCC $6.22
  • VRNA $896.59
  • Revenue Next Year
  • WCC $4.85
  • VRNA $77.56
  • P/E Ratio
  • WCC $16.95
  • VRNA N/A
  • Revenue Growth
  • WCC 1.30
  • VRNA N/A
  • 52 Week Low
  • WCC $125.21
  • VRNA $27.54
  • 52 Week High
  • WCC $228.35
  • VRNA $106.45
  • Technical
  • Relative Strength Index (RSI)
  • WCC 49.91
  • VRNA 73.36
  • Support Level
  • WCC $211.77
  • VRNA $106.15
  • Resistance Level
  • WCC $220.86
  • VRNA $106.42
  • Average True Range (ATR)
  • WCC 5.05
  • VRNA 0.20
  • MACD
  • WCC -1.15
  • VRNA -0.16
  • Stochastic Oscillator
  • WCC 17.73
  • VRNA 97.90

About WCC WESCO International Inc.

Wesco can be traced back to the late 1800s but was officially founded in 1922, acting as the distribution arm of Westinghouse Electric. Throughout the 1900s, Wesco entered and subsequently exited the consumer electronics, transit, bottling, and nuclear plant distribution markets. It was sold to a private equity firm in 1994 and then went public in 1999, and numerous acquisitions have since been made to fill the gaps in Wesco's geographical and product coverage. Today, the firm primarily distributes electrical, networking, security, and utility equipment used in the construction and repair of structures such as offices, data centers, power transmission lines, and manufacturing plants. Wesco has operations around the globe but generates the majority of its revenue in the United States.

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Share on Social Networks: